NVS - Spark Newswire

2 minute read

Novartis Received Positive Chmp Opinion for Scemblix, a Novel Treatment for Adult Patients With Chronic Myeloid Leukemia

Today, 5:35 PM

Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization for Scemblix® (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more t

NVS

1 minute read

Novartis Announces $250M In R&D Funding For Neglected Tropical Diseases, Malaria

By Vandana Singh

Today, 5:35 PM

Novartis AG (NYSE:NVS) is pledging $250 million into R&D for new treatments of neglected tropical diseases (NTD) and malaria, with an…

NVS

1 minute read

FDA Gives Approval For Novartis’ Tafinlar + Mekinist Broadens BRAF/MEK Cancer Combo Use

By Vandana Singh

Today, 5:35 PM

The FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) pairing of Tafinlar and Mekinist for any advanced solid tumors with the BRAF…

NVS

4 minute read

The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma’s Alzheimer’s Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral

By Vandana Singh

Today, 5:35 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

APLS

2 minute read

Novartis Received European Commission Approval for Tabrecta for the Treatment of METex14 Skipping Advanced Non-small Cell Lung Cancer

By Charles Gross

Today, 5:35 PM

Novartis announced today that the European Commission (EC) approved Tabrecta® (capmatinib) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to mesenchymal-epithelial-transition factor gene (MET) exon 14 (METex14) skipping who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemoth

NVS

10 minute read

FDA
News

Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

By Benzinga Newsdesk

Today, 5:35 PM

Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease - Precision to Receive $75

DTIL